Postoperative Insulin Intervention After Pancreatectomy in nDM Patients

What Was Tested

This registered not phased trial tested Insulin (regular human) for pancreatitis (after the acute phase).

It had two arms (groups): No Insulin Infusion Group (experimental) and Standard Insulin Infusion Group (active comparator).

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 290 planned participants were the target.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adults aged 18 to 80 years. Patients without a prior diagnosis of diabetes mellitus. Patients scheduled to undergo pancreatectomy for periampullary tumors or pancreatic tumors. Ability to understand the study and provide written informed consent.

The full record lists 4 inclusion and 5 exclusion criteria; among the exclusions: patients diagnosed with pancreatic adenocarcinoma; patients undergoing total pancreatectomy; patients undergoing hepatopancreatoduodenectomy (hpd) or with a history of prior hepatectomy.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Insulin (regular human) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the pancreatitis (after the acute phase) participants stayed in one arm throughout.

Being open-label, the Insulin (regular human) study did not mask who received what.

It started in 2026-05-18 with completion listed for 2029-12-31.

It ran at 1 site in South Korea.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Mean Blood Glucose Level (Average of Daily Mean Values from Postoperative Day 0 to 3) (time frame: From postoperative day 0 through postoperative day 3).

It also tracked 7 secondary outcomes, for example Mean Blood Glucose Level on Postoperative Day 0, Mean Blood Glucose Level on Postoperative Day 1, Mean Blood Glucose Level on Postoperative Day 2, Mean Blood Glucose Level on Postoperative Day 3, Postoperative Blood Glucose Variability and Incidence of Hypoglycemia.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Insulin (regular human) in 290 people with pancreatitis (after the acute phase).

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin (regular human) compound page, Pancreatitis (after the acute phase) research.